Where are we going with SSRIs?

European Neuropsychopharmacology

Volumn 9, Issue SUPPL. 3, 1999, Pages

  Isaac, Michael ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Anxiety disorders; Augmentation; Depression; Pindolol; Selective serotonin reuptake inhibitor; Social anxiety disorder Social phobia

Indexed keywords

ANTIDEPRESSANT AGENT; NORTRIPTYLINE; PAROXETINE; PINDOLOL; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ANXIETY NEUROSIS; CONFERENCE PAPER; DEPRESSION; HEART RATE; HUMAN; ISCHEMIC HEART DISEASE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL;

EID: 0032775585     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(99)00028-0     Document Type: Conference Paper

References (43)

1. Allgulander C., Cloninger C.R., Przybeck T.R., Brandt L. Changes on the Temperament and Character Inventory in volunteers with generalized anxiety disorder. Psychopharmacol. Bull. 34:1998;165-166.
2. Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry. 51:1994;248-251.
3. Baker D., Bardy K., Glodstein S., Farfel G. Double-blind flexible dose multicenter study of sertraline and placebo in outpatients with post-traumatic stress disorder. Eur. Neuropsychopharm. 8:(2):1998;S261.
4. Baldwin, D., Bobes, J., Stein, D.J., Scharwächter, I., Faure, M. on behalf of the Paroxetine Study Group, 1999. A randomised, double-blind, placebo-controlled study of paroxetine in the treatment of social phobia/social anxiety disorder. Br. J. Psychiatry. In press.
5. Berman R.M., Darnell A.M., Miller H.L., Anand A., Charney D.S. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am. J. Psychiatry. 154:1997;37-43.
6. Blier P., Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J. Clin. Psychopharmacol. 15:1995;217-222.
7. Blier P., Bergeron R. Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. Int. Clin. Psychopharmacol. 11:1996;37-44.
8. Bordet R., Thomas P., Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Reseau de Recherche et d'Experimentation Psychopharmacologique. Am. J. Psychiatry. 155:1998;1346-1351.
9. Brady K.T., Sonne S.C., Roberts J.M. Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. J. Clin. Psychiatry. 56:1995;502-505.
10. Contu A. Depression in breast cancer patients - comparison of paroxetine and amitriptyline. Eur. Neuropsychopharmacol. 7:(2):1997;S178-S179.
11. Cryan J.F., McGrath C., Leonard B.E., Norman T.R. Combining pindolol and paroxetine in an animal model of chronic antidepressant action - can early onset of action be detected? Eur. J. Pharmacol. 352:1998;23-28.
12. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicentre study. Psychopharmacology. 90:1986;131-138.
13. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicentre study. J. Affect. Disord. 18:1990;289-299.
14. Dannon P.N., Hirschmann S., Kindler S., Iancu T., Dolberg O.T., Grunhaus L.J. Pindolol augmentation in the treatment of resistant panic disorder: a double-blind placebo-controlled trial. 10th European College of Neuropsychopharmacology Congress, Vienna. Abstract P.3.013 :1997.
15. De Boer M., Op den Velde W., Falger P.J., Hovens J.E., De Groen J.H., Van Duijn H. Fluvoxamine treatment for chronic PTSD: a pilot study. Psychother. Psychosom. 57:1992;158-163.
16. Dyer A.R., Persky V., Stamler J., Paul O., Shekelle R.B., Berkson D.M., Lepper M., Schoenberger J.A., Lindberg H.A. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am. J. Epidemiol. 112:1980;736-749.
17. Frasure-Smith N.J., Lesperance F., Talajic M. Depression following myocardial infarction: impact on 6-month survival. J. Am. Med. Assoc. 270:1993;1819-1825.
18. Gillum R.F., Makue D.M., Feldman J.J. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. Am. Heart J. 121:1991;172-177.
19. Hjorth S. Serotonin 5-HT1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo - a microdialysis study. J. Neurochem. 60:1993;776-779.
20. Hunter B. Depression associated with rheumatoid arthritis - comparison of paroxetine and amitriptyline. 10th European College of Neuropsychopharmacology Congress, Vienna. Poster presentation :1997.
21. Invemizzi R., Belli S., Samanin R. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res. 584:1992;322-324.
22. Kannel W.B., Kannel C., Paffenbarger R.S. Jr., Cupples L.A. Heart rate and cardiovascular mortality: the Framingham Study. Am. Heart J. 113:1987;1489-1494.
23. Katona C.L.E., Hunter B.N., Bray J. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int. J. Geriatr. Psychiatry. 13:1988;100-108.
24. Kessler R.C., Sonnega A., Bromet E.J., Hughes M., Nelson C.B. Posttraumatic stress disorder in the National Comorbidity Survey. Arch. Gen. Psychiatry. 52:1995;1048-1060.
25. Koran L.M., Mueller K., Maloney A. Will pindolol augment the response to a serotonin reuptake inhibitor in obsessive-compulsive disorder? J. Clin. Psychopharmacol. Lett. 16:1996;253-254.
26. Lépine J.-P., Lellouch J. Classification and epidemiology of social phobia. Eur. Arch. Psychiatry Clin. Neurosci. 244:1995;290-296.
27. Marshall R.D., Schneier F.R., Fallon B.A., et al. An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. J. Clin. Psychopharmacol. 18:1998;10-18.
28. Mundo E., Guglielmo E., Bellodi L. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int. Clin. Psychopharmacol. 13:1998;219-224.
29. Nagy L.M., Morgan III C.A., Southwick S.M., Charney D.S. Open prospective trial of fluoxetine for posttraumatic stress disorder. J. Clin. Psychiatry. 13:1993;107-113.
30. Olver J.S., Burrows G.D. Elevated plasma paroxetine concentrations in a patient treated with a combination of paroxetine and pindolol. Int. J. Psych. Clin. Pract. 2:1998;225-227.
31. Perez V., Gilaberte I., Fames D., Alvarez E., Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 349:1997;1594-1597.
32. Rocca P., Fonzo V., Scotta M., Zanalda E., Ravizza L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta. Psychiatr. Scand. 95:1997;444-450.
33. Roose S.P., Laghrissi-Thode F., Kennedy J.S., et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. J. Am. Med. Assoc. 279:1998;287-291.
34. Roose S.P., Glassman A.H., Attia E., Woodring S., Gardinia E.G.V., Bigger J.T. Jr. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am. J. Psychiatry. 155:1998;660-665.
35. Rothbaum B.O., Ninan P.T., Thomas L. Sertraline in the treatment of rape victims with posttraumatic stress disorder. Trauma Stress. 9:1996;865-871.
36. Schleifer S.J., Macari-Hinson M.M., Coyle D.A., et al. The nature and course of depression following myocardial infarction. Arch. Intem. Med. 149:1989;1785-1789.
37. Stein M.B., Liebowitz M.R., Lydiard R.B., Pitts C.D., Bushnell W., Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder). J. Am. Med. Assoc. 280:1998;708-713.
38. Tome M.B., Isaac M.T. One year real world prospective follow-up study of a major depressive episode of patients treated with paroxetine and pindolol or paroxetine for 6 weeks. Int. Clin. Psychopharmacol. 13:1998;169-174.
39. Tome M.B., Isaac M.T., Harte R., Holland C. Paroxetine and pindolol: a randomised trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int. Clin. Psychopharmacol. 12:1997;81-89.
40. van der Kolk B.A., Dreyfuss D., Michaels M., et al. Fluoxetine in posttraumatic stress disorder. J. Clin. Psychiatry. 55:1994;517-522.
41. Wittchen H.U., Zhao S., Kessler R.C., Eaton W.W. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch. Gen. Psychiatry. 51:1994;355-364.
42. Zanardi R., Artigas F., Franchini L., et al. How long should pindolol be associated with paroxetine to improve the antidepressant response? J. Clin. Psychopharmacol. 17:1997;446-450.
43. Zygmont M., Prigerson H.G., Houck P.R., et al. A post hoc comparison of paroxetine and nortriptyline for symptoms of traumatic grief. J. Clin. Psychiatry. 5:1998;241-245.